In short
Clinical trials are studying Vh4524184 in adults living with HIV-1. These studies look at antiviral activity, treatment response, and safety in treatment-naïve people, meaning people who have not yet used HIV treatment. The trials include Phase 2 research in different adult groups.
Key points
- Clinical trials of Vh4524184 are studying adults living with HIV-1 who have not used HIV treatment before. The research includes two Phase 2 interventional studies. One completed study tested short-term antiviral activity during 10 days of monotherapy, and the other authorised study is testing longer treatment regimens over 12 months. The main outcomes measure change in plasma HIV-1 RNA and whether the virus stays below a set level in the blood. Together, these trials are looking at how well Vh4524184 regimens control HIV-1 in treatment-naïve adults.
Trial overview
Two interventional studies are listed for Vh4524184 in adults with HIV-1. Both studies are in Phase 2, which means they are designed to learn more about how well the treatment works while still collecting important safety information.
One study is completed and looked at short-term antiviral activity over 10 days. The other study is authorised and is testing longer treatment regimens over 12 months in treatment-naïve adults living with HIV-1.
Who can join these studies
The target population in both trials is treatment-naïve adults living with HIV-1. Treatment-naïve means the person has not yet received HIV treatment.
Both studies focus on people with HIV infections, and the authorised study describes participants as viremic adults, meaning adults whose virus can be measured in the blood.
Study design and phases
The completed study, 2023-507173-18-00, was a Phase 2 proof-of-concept trial. Proof-of-concept means the study was designed to see whether the treatment showed early signs of working in people.
This study tested Vh4524184 during 10 days of monotherapy, meaning the study drug was given alone in that part of the trial. It enrolled 28 participants.
The authorised study, 2025-521918-26-00, is also Phase 2 and is called the INNOVATE study. It plans to enroll 440 participants and compares oral Vh4524184 regimens with a control arm using DTG/3TC fixed-dose combination oral treatment.
What the trials measure
The main outcome in the completed study was the maximum change from baseline in log10 plasma HIV-1 RNA through Day 10. In simple words, this measures the biggest drop in virus level in the blood during the first 10 days.
The main outcome in the authorised study is the number of participants with plasma HIV-1 RNA below 50 copies/mL at Month 12 using the FDA snapshot method. This shows how many people reach a very low virus level after 12 months of treatment.
Details of each trial
2023-507173-18-00 was a completed Phase 2 proof-of-concept study in treatment-naïve adults living with HIV-1. The brief summary says the purpose was to evaluate the antiviral activity of Vh4524184 during 10 days of monotherapy.
2025-521918-26-00 is an authorised Phase 2b study, also in treatment-naïve people with HIV-1. The brief summary says it is evaluating oral Vh4524184-containing regimens compared with a DTG/3TC fixed-dose combination oral control arm in treatment-naïve viremic adults living with HIV-1.
The listed interventions include oral Vh4524184 in both trials. The authorised study also lists Dovato 50 mg/300 mg film-coated tablets and Descovy 200 mg/25 mg film-coated tablets as comparison treatments.
What these studies may mean for patients
These trials are trying to show whether Vh4524184 can reduce HIV-1 in the blood in adults who have not yet started treatment. The studies are not about long-term cure; they are about measuring early and later treatment response.
For patients, the most important points are the study population, the study phase, and the main outcomes. Here, the focus is on treatment-naïve adults with HIV-1, Phase 2 research, and blood tests that measure how much virus is present.